University of Texas M.D. Anderson Cancer SPORE-Leukemia

描述（由申请人提供）：德克萨斯大学M.D.安德森癌症中心正在提出一个白血病研究卓越专业项目（SPORE）。该项目的主要目标是培养和促进白血病生物学、遗传学和临床方面的创新和重要的转化研究，以提高对白血病的理解、治疗和预后。白血病孢子的多学科研究小组将通过实验室、流行病学和临床调查的有效整合来实现这一目标。这种活性将进一步加深我们对白血病遗传易感性和白血病发生分子过程的理解，从而导致白血病的新型分子靶向策略。《孢子》设计了6个研究项目和3个核心资源，以及发展研究和职业发展计划。这些研究项目的目标是白血病中重要的特定区域。

DESCRIPTION (provided by applicant): The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. Such activity will further our understanding of genetic susceptibility and leukemogenic molecular processes in leukemia, leading to novel, molecularly targeted strategies in leukemia. The SPORE is designed with 6 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia. Project 1 - Epigenetics of Drug Resistance in Acute Leukemia -targets methylation for therapy in leukemia Project 2 -Adoptive Cellular Therapy of Myeloid Leukemia - targets the use of MPO-Specific Cytotoxic T Lymphocytes (CTL) to treat leukemia Project 3 - Concerted Blockade of Oncoprotein Activity - targets sequential DNA, RNA and oncoprotein blockage in leukemia Project 4 -PPAR-gamma Nuclear Transcription Factor: A Novel Target for Leukemia Therapy - targets PPAR-gamma expression for leukemia therapy Project 5 - Molecular Epidemiology of AML Risk and Progression - evaluates genetic-molecular susceptibilities to development of AML through studies of relevant detoxifying and carcinogenesis-promoting pathways Project 6 - Response of AML Patients to FLT3 Inhibitors - targets FLT3 ligand inhibition in leukemias expressing FLT3 mutations or internal tandem duplication (ITD) Core and other resources are: Core A - Administration, Core B - Pathology and Tissue, Core C - Biostatistics & Data Management, Developmental Research Program, and Career Development Program. Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis.